IL298135A - Combination therapy for ttr amyloidosis - Google Patents

Combination therapy for ttr amyloidosis

Info

Publication number
IL298135A
IL298135A IL298135A IL29813522A IL298135A IL 298135 A IL298135 A IL 298135A IL 298135 A IL298135 A IL 298135A IL 29813522 A IL29813522 A IL 29813522A IL 298135 A IL298135 A IL 298135A
Authority
IL
Israel
Prior art keywords
antibody
ttr
attr
seq
tafamidis
Prior art date
Application number
IL298135A
Other languages
English (en)
Hebrew (he)
Original Assignee
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Ag filed Critical Neurimmune Ag
Publication of IL298135A publication Critical patent/IL298135A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL298135A 2020-05-12 2021-05-12 Combination therapy for ttr amyloidosis IL298135A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20174177 2020-05-12
PCT/EP2021/062706 WO2021228987A1 (en) 2020-05-12 2021-05-12 Combination therapy for ttr amyloidosis

Publications (1)

Publication Number Publication Date
IL298135A true IL298135A (en) 2023-01-01

Family

ID=70682637

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298135A IL298135A (en) 2020-05-12 2021-05-12 Combination therapy for ttr amyloidosis

Country Status (13)

Country Link
US (1) US20230183329A1 (https=)
EP (1) EP4149972A1 (https=)
JP (1) JP7834032B2 (https=)
KR (1) KR20230009950A (https=)
CN (1) CN115551886A (https=)
AU (1) AU2021272369A1 (https=)
BR (1) BR112022023031A2 (https=)
CA (1) CA3172824A1 (https=)
CL (2) CL2022003141A1 (https=)
CO (1) CO2022017877A2 (https=)
IL (1) IL298135A (https=)
MX (1) MX2022014223A (https=)
WO (1) WO2021228987A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099788A1 (en) * 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
AU2023382527A1 (en) * 2022-11-15 2025-06-26 Alexion Pharmaceuticals, Inc. Methods for treating or preventing transthyretin-mediated amyloidosis
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
WO2025104243A1 (en) 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis
WO2025238147A1 (en) * 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US10344080B2 (en) * 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
EP3101131B1 (en) 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
EP3981874A1 (en) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anti-transthyretin human antibody
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
CU24731B1 (es) * 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
CU20200042A7 (es) * 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
US20210400932A1 (en) 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model

Also Published As

Publication number Publication date
CL2022003141A1 (es) 2023-07-21
WO2021228987A1 (en) 2021-11-18
EP4149972A1 (en) 2023-03-22
CL2025001129A1 (es) 2025-11-28
US20230183329A1 (en) 2023-06-15
AU2021272369A1 (en) 2023-01-19
MX2022014223A (es) 2023-04-14
CO2022017877A2 (es) 2023-02-27
JP7834032B2 (ja) 2026-03-23
KR20230009950A (ko) 2023-01-17
JP2023525790A (ja) 2023-06-19
BR112022023031A2 (pt) 2022-12-20
CA3172824A1 (en) 2021-11-18
CN115551886A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
JP6994484B2 (ja) 高脂血症を処置するためのpcsk9阻害剤の使用
US20230183329A1 (en) Combination therapy for ttr amyloidosis
US12606638B2 (en) Dosing regimens for use with PCSK9 inhibitors
TW200815468A (en) Use of organic compounds
US20160271218A1 (en) Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
US20090186040A1 (en) DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT
KR20220125249A (ko) 동형접합 가족성 고콜레스테롤혈증을 치료하기 위한 pcsk9 억제제의 용도
US20160106837A1 (en) Combination of cd37 antibodies with chlorambucil
ES2779126T3 (es) Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
WO2020186256A1 (en) Methods of treating immunoglobulin a nephropathy (igan) using axl decoy receptors
US20250059289A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
TW202535943A (zh) 改善抗FcRn療法之方法
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA051213B1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
HK40059806A (en) Dosing regimens for use with pcsk9 inhibitors